145 related articles for article (PubMed ID: 37864443)
21. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
[TBL] [Abstract][Full Text] [Related]
23. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.
Buhl AM; James DF; Neuberg D; Jain S; Rassenti LZ; Kipps TJ
Eur J Haematol; 2011 May; 86(5):405-411. PubMed ID: 21323738
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
D'Arena G; Sgambato A; Volpe S; Coppola G; Amodeo R; Tirino V; D'Auria F; Statuto T; Valvano L; Pietrantuono G; Deaglio S; Efremov D; Laurenti L; Aiello A
Hematol Oncol; 2022 Dec; 40(5):835-842. PubMed ID: 35667043
[TBL] [Abstract][Full Text] [Related]
25. Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology.
Peková S; Bezdícková L; Smolej L; Kozák T; Hochová I; Zák P; Tomsíková L; Průcha M
Mol Diagn Ther; 2007; 11(5):325-35. PubMed ID: 17963420
[TBL] [Abstract][Full Text] [Related]
26. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
28. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ; van der Klift MY; Kolijn PM; Davi F; Kavelaars FG; de Jonge E; Robrecht S; Assmann JLJC; van der Straten L; Ritgen M; Westerweel PE; Fischer K; Goede V; Hallek M; Levin MD; Langerak AW
Blood; 2023 Feb; 141(5):519-528. PubMed ID: 36084320
[TBL] [Abstract][Full Text] [Related]
29. A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia.
Sartor MM; Gottlieb DJ
Cytometry B Clin Cytom; 2013 Mar; 84(2):96-103. PubMed ID: 23283845
[TBL] [Abstract][Full Text] [Related]
30. Assessing minimal residual disease in chronic lymphocytic leukemia.
Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.
Tomuleasa C; Selicean C; Cismas S; Jurj A; Marian M; Dima D; Pasca S; Petrushev B; Moisoiu V; Micu WT; Vischer A; Arifeen K; Selicean S; Zdrenghea M; Bumbea H; Tanase A; Grewal R; Pop L; Aanei C; Berindan-Neagoe I
Crit Rev Clin Lab Sci; 2018 Aug; 55(5):329-345. PubMed ID: 29801428
[TBL] [Abstract][Full Text] [Related]
32. Eradication of minimal residual disease in chronic lymphocytic leukemia.
Schweighofer CD; Hallek M; Wendtner CM
Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
[TBL] [Abstract][Full Text] [Related]
33. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
34. Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.
Farren TW; Sadanand KS; Agrawal SG
Front Oncol; 2020; 10():597730. PubMed ID: 33344247
[TBL] [Abstract][Full Text] [Related]
35. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
[TBL] [Abstract][Full Text] [Related]
36. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
37. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
[TBL] [Abstract][Full Text] [Related]
38. From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
Riva G; Luppi M; Tagliafico E
Br J Haematol; 2023 Aug; 202(4):715-717. PubMed ID: 37092558
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
40. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
